Two-year outcomes after transcatheter tricuspid repair without cross-over in the randomized Tri-fr trial

Reported from ACC.26

Alex Sticchi interviews Erwan Donal on the 2-year outcomes of the TRI-FR randomised trial evaluating transcatheter tricuspid edge-to-edge repair (T-TEER) versus medical therapy alone, as presented at ACC.26 in New Orleans.

The study confirms earlier 1-year benefits on symptoms and quality of life, now extending to a significant reduction in hard clinical events. At a median follow-up of 30 months, fewer deaths, heart failure hospitalisations, and surgeries were observed in the T-TEER group, highlighting a prognostic impact beyond symptomatic relief. These findings reinforce the role of treating severe tricuspid regurgitation, previously considered mainly a risk marker, and support a shift toward earlier interventional management.